Last checked at (Sharecast News) - United States healthcare software company Craneware reported a 6% improvement in revenue in its final results on Tuesday, to $75.6m.
The AIM-traded firm said its three-year total visible revenue for the year ended 30 June, including the contribution from Sentry from 13 July onwards, was $471.2m, up from $196.2m at the same time last year.
Adjusted EBITDA was 8% firmer year-on-year at $27.1m, while profit before tax fell to $13.2m from $19.3m, which the board said reflected exceptional costs associated with the funding of acquisitions.
Basic adjusted earnings per share increased 6% to 69 cents, and adjusted diluted earnings per share increased to 68.1 cents from 64.4 cents.
The company said basic earnings per share came in at 48.1 cents, down from 62.8 cents, and diluted earnings per share were 47.5 cents, falling from 61.9 cents.
Operating cash conversion was described as "strong", at 99% of adjusted EBITDA, rising from 92% in the 2020 financial year.
Cash at year-end totalled $235.6m, up from $47.9m a year earlier, after the company raised $187.3m net via a share placing, and prior to the completion of the Sentry acquisition.
The board proposed an increase in the final dividend to 15.5p, or 21.47 cents, per share, up from 15p and 18.45 cents for 2020, respectively.
That would make for a total dividend for the year of 27.5p, or 38.1 cents, per share, rising from 26.5p and 32.60 cents a year ago.
Looking ahead, the company said it was seeing continued sales momentum across the now-enlarged group, with the integration of Sentry proceeding faster than its initial expectations.
It said the long-term transition to "value-based care" in the sector provided an ongoing basis for growth, with the board saying it was "confident" in a return to double-digit organic growth in future years.
"Our team delivered a positive performance in the year, against the ongoing backdrop of the pandemic, supporting our customers through an incredibly challenging period while continuing to execute on our strategy," said chief executive officer Keith Neilson.
"We experienced continued sales momentum and strong adoption of our Trisus cloud based platform, paving the way for accelerated future growth.
"The successful completion of the acquisition of Sentry Data Systems following the end of the year marks a transformational point in our journey, considerably expanding our customer base, data sets, product offering and market presence."
Neilson said the combined companies would offer healthcare organisations "innovative" ways to measurably improve operational and financial performance, to generate sustainable margins.
"With a strong balance sheet, high levels of recurring revenues, high customer retention rates and visible revenue in the next three years of $471.2m, we have a strong financial foundation from which to accelerate growth and to fulfil our potential, thereby increasing future shareholder value.
"We have enjoyed early sales momentum across the now-enlarged group, and with our expanded opportunity we look to the future with considerable excitement and confidence as we work with the Sentry team to transform the business of US healthcare."
At 1011 BST, shares in Craneware were up 0.87% at 2,320p.
7 Mar 2014 14:55
UK Earnings, Trading Statements Calendar - Week Ahead
| Read more 16 Jan 2014 12:19 Craneware Confident In Meeting Full-Year Expectations On Strong First-HalfLONDON (Alliance News) - Healthcare company Craneware PLC said Thursday that it was confident in meeting market expectations for the full-year as it saw revenue and earnings before interest, tax, depreciation and amortisation increase in the six months ended December 31. The company expects Read more16 Jan 2014 10:15 UK BROKER RATING CHANGES: Liberum, Panmure Raise Astra TargetLONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning: 16 Jan 2014 08:59  Thursday broker round-up UPDATEAberdeen Asset Management: Canaccord Genuity cuts target price from 586p to 540p, while its buy recommendation remains unchanged. Anglo American: UBS ups target price from 1500p to 1580p upgrading from neutral to buy. Antofagasta: Investec reduces target price from 716p to 685p maintaining a sell Read more16 Jan 2014 08:21 UK MORNING BRIEFING: Shares Down; Sports Direct Ups Interest In DebenhamsLONDON (Alliance News) - UK shares have opened mostly lower Thursday despite a strong lead from the US, as investors digest a rush of UK company announcements. 12 Nov 2013 09:20 Tuesday broker round-up UPDATEAccesso: Canaccord Genuity raises target price from 680p to 770p and keeps a buy recommendation. Andor Technology: FinnCap places both its target price (prev.: 390p) and its hold recommendation under review. Babcock International: Jefferies increases target price from 1250p to 1600p retaining a bu Read more10 Sep 2013 09:34 10 Sep 2013 08:17 Tuesday broker round-up UPDATEAfrican Barrick Gold: Investec shifts target price from 135p to 137p, while downgrading from hold to sell. Aquarius Platinum: JP Morgan moves target price from 39p to 49p, while downgrading from neutral to underweight. Citi lowers target price from 66p to 54p and downgrades from buy to neutral. As Read more10 Sep 2013 07:18 Craneware profit slips as revenue holds upEdinburgh based software company Craneware said full year revenue was marginally ahead of last year, but profit was hit after it failed to secure a major contract. The group, which provides revenue assessing software to US hospitals, said revenue increased 1% to $41.5m for the year ended June 30th Read more26 Jun 2013 08:02 Craneware earnings to be below market forecastsCraneware warned that revenues and earnings for the year will be in line or marginally ahead of last year but below current market forecasts. The Scotland-based firm, which provides revenue assessing software to US hospitals, said it continues to see increased levels of sales activity and conversio Read more26 Jun 2013 07:30 Wednesday broker round-up UPDATEACM Shipping Group: Espirito Santo increases target price from 150p to 185p keeping a buy recommendation. Afren: Canaccord Genuity moves target price from 210p to 220p and keeps a buy recommendation. Aggreko: Deutsche Bank cuts target price from 2250p to 2100p, while its buy recommendation remains Read more27 Feb 2013 16:12 3i Chief adds 2.5m shares to stakeSimon Borrows, the Chief Executive of 3i Group, the international investor focused on mid-market private equity, this week bought 2.5m 3i shares in three tranches. The three tranches consisted of 550,000 shares purchased at 308.22p, 374,809 at 312.38p, and 1.6m at 305.84p. Altogether the purchases Read more27 Feb 2013 08:11 Wednesday broker round-up UPDATE: Panmure Gordon reduces target price from 2159p to 1742p and reiterates its hold recommendation. Antofagasta: JP Morgan cuts target price from 1485p to 1400p, while retaining its overweight rating. Barclays: Numis raises target price from 351p to 400p and upgrades to buy. BT Group: UBS moves tar Read more26 Feb 2013 09:22  STOCKS NEWS EUROPE-UK small caps dip 0.7 pct in early dealsThe FTSE Small Cap index falls 0.7 percent early on, faring better than the 1.2 percent drops on the FTSE 100 and FTSE 250. London-listed rare earths mining specialist Rare Earths Global tumbles 21.5 percent after it says upheaval in the rare earths industry and sliding prices mean it will Read moreLogin to your accountDon't have an account? Click here to register.Quickpicks are a member only featureLogin to your accountDon't have an account? Click here to register. |